Given the pivotal role of astrogliosis in the pathogenesis of Alzheimer’s disease, growing evidence from large patient cohorts suggests that GFAP is a reliable biomarker for distinguishing Alzheimer’s disease from other neurodegenerative disorders even at early stages.9,19 Furthermore, GFAP is highly brain-specific and is not extensively secreted into biofluids under physiological conditions, reinforcing its relevance as a neurodegenerative brain disease biomarker.139. The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.